BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012; 10: 1034-41. e1. [PMID: 22642955 DOI: 10.1016/j.cgh.2012.05.016] [Cited by in Crossref: 153] [Cited by in F6Publishing: 145] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Bajaj JS. Introduction and setting the scene: New nomenclature of hepatic encephalopathy and American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines. Clin Liver Dis (Hoboken) 2017;9:48-51. [PMID: 30992956 DOI: 10.1002/cld.610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol. 2017;5:142-151. [PMID: 28660152 DOI: 10.14218/jcth.2016.00069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
3 Hanna A, Gill I, Imam Z, Halalau A, Jamil LH. Low yield of head CT in cirrhotic patients presenting with hepatic encephalopathy. BMJ Open Gastroenterol 2021;8:e000609. [PMID: 34083228 DOI: 10.1136/bmjgast-2021-000609] [Reference Citation Analysis]
4 Wang Z, Chu P, Wang W. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther. 2019;13:1-11. [PMID: 30587923 DOI: 10.2147/dddt.s172324] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
5 Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis. 2017;21:579-594. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
6 Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715-735. [PMID: 25042402 DOI: 10.1002/hep.27210] [Cited by in Crossref: 879] [Cited by in F6Publishing: 680] [Article Influence: 109.9] [Reference Citation Analysis]
7 Wijarnpreecha K, Werlang M, Panjawatanan P, Kroner PT, Cheungpasitporn W, Lukens FJ, Pungpapong S, Ungprasert P. Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis. Ann Hepatol 2020;19:245-50. [PMID: 31422030 DOI: 10.1016/j.aohep.2019.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 García-Cortés M, Ortega-Alonso A, Andrade RJ. Safety of treating acute liver injury and failure. Expert Opin Drug Saf 2021;:1-13. [PMID: 34254839 DOI: 10.1080/14740338.2021.1955854] [Reference Citation Analysis]
9 Kim Y, Reddy S, Mouchli M, Summey R, Walsh C, Mir A, Bierle L, Rubio M. Gender-Specific Risk Factors Contributing to Mortality in Patients Hospitalized With Alcoholic Cirrhosis. Cureus 2021;13:e16271. [PMID: 34377607 DOI: 10.7759/cureus.16271] [Reference Citation Analysis]
10 Seraj SM, Campbell EJ, Argyropoulos SK, Wegermann K, Chung RT, Richter JM. Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. World J Gastroenterol 2017; 23(37): 6868-6876 [PMID: 29085229 DOI: 10.3748/wjg.v23.i37.6868] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
11 Gupta P, Vyas S, Salan T, Jain C, Taneja S, Dhiman RK, Singh P, Ahuja CK, Ray N, Govind V. Whole brain atlas-based diffusion kurtosis imaging parameters for evaluation of minimal hepatic encephalopathy. Neuroradiol J 2021;:19714009211026924. [PMID: 34187242 DOI: 10.1177/19714009211026924] [Reference Citation Analysis]
12 Iqbal U, Jadeja RN, Khara HS, Khurana S. A Comprehensive Review Evaluating the Impact of Protein Source (Vegetarian vs. Meat Based) in Hepatic Encephalopathy. Nutrients 2021;13:370. [PMID: 33530344 DOI: 10.3390/nu13020370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Asrani SK, Simonetto DA, Kamath PS. Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol 2015;13:2128-39. [PMID: 26188138 DOI: 10.1016/j.cgh.2015.07.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
14 Fabrellas N, Moreira R, Carol M, Cervera M, de Prada G, Perez M, Vazquez E, Sola M, Sancho R, Juanola A, Pose E, Solé C, Graupera I, Solà E, Kamath PS, Ginès P. Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers. Clin Transl Gastroenterol 2020;11:e00159. [PMID: 32352686 DOI: 10.14309/ctg.0000000000000159] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
15 Ganapathy D, Acharya C, Lachar J, Patidar K, Sterling RK, White MB, Ignudo C, Bommidi S, DeSoto J, Thacker LR, Matherly S, Shaw J, Siddiqui MS, Puri P, Sanyal AJ, Luketic V, Lee H, Stravitz RT, Bajaj JS. The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions. Liver Int. 2017;37:1843-1851. [PMID: 28618192 DOI: 10.1111/liv.13494] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
16 Oofuvong M, Geater AF, Chongsuvivatwong V, Chanchayanon T, Sriyanaluk B, Suwanrat B, Nuanjun K. Does perioperative respiratory event increase length of hospital stay and hospital cost in pediatric ambulatory surgery? PLoS One 2021;16:e0251433. [PMID: 33984031 DOI: 10.1371/journal.pone.0251433] [Reference Citation Analysis]
17 Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nat Rev Neurosci. 2013;14:851-858. [PMID: 24149188 DOI: 10.1038/nrn3587] [Cited by in Crossref: 196] [Cited by in F6Publishing: 186] [Article Influence: 21.8] [Reference Citation Analysis]
18 Roggeri DP, Roggeri A. Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy. Hepat Med 2017;9:37-43. [PMID: 29026340 DOI: 10.2147/HMER.S146438] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Patel AV, Wade JB, Thacker LR, Sterling RK, Siddiqui MS, Stravitz RT, Sanyal AJ, Luketic V, Puri P, Fuchs M, Matherly S, White MB, Unser A, Heuman DM, Bajaj JS. Cognitive reserve is a determinant of health-related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for end-stage liver disease score. Clin Gastroenterol Hepatol 2015;13:987-91. [PMID: 25445772 DOI: 10.1016/j.cgh.2014.09.049] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
20 Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 2015;:CD001939. [PMID: 26377410 DOI: 10.1002/14651858.CD001939.pub3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
21 Gentry SE, Chow EK, Dzebisashvili N, Schnitzler MA, Lentine KL, Wickliffe CE, Shteyn E, Pyke J, Israni A, Kasiske B, Segev DL, Axelrod DA. The Impact of Redistricting Proposals on Health Care Expenditures for Liver Transplant Candidates and Recipients. Am J Transplant 2016;16:583-93. [PMID: 26779694 DOI: 10.1111/ajt.13569] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
22 Sood KT, Wong RJ. Hepatic Encephalopathy is a Strong Predictor of Early Hospital Readmission Among Cirrhosis Patients. J Clin Exp Hepatol 2019;9:484-90. [PMID: 31571775 DOI: 10.1016/j.jceh.2019.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Haj M, Rockey DC. Predictors of clinical outcomes in cirrhosis patients. Curr Opin Gastroenterol. 2018;34:266-271. [PMID: 29846263 DOI: 10.1097/mog.0000000000000450] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
24 Bajaj JS. Hepatic encephalopathy: classification and treatment. J Hepatol 2018;68:838-9. [PMID: 29756596 DOI: 10.1016/j.jhep.2017.11.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
25 Hunt TD, Guglielminotti J, Li G. Costs Associated with Anesthesia-Related Adverse Events During Labor and Delivery in New York State, 2010: . Anesthesia & Analgesia 2016;122:2007-16. [DOI: 10.1213/ane.0000000000001291] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
26 Martí-carvajal AJ, Gluud C, Arevalo-rodriguez I; Cochrane Hepato-Biliary Group. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011451] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Yanny B, Winters A, Boutros S, Saab S. Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. Clin Liver Dis 2019;23:607-23. [PMID: 31563214 DOI: 10.1016/j.cld.2019.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Córdoba J, Ventura-cots M. Drug-induced removal of nitrogen derivatives in urine: A new concept whose time has come: Cordoba and Ventura-Cots. Hepatology 2014;59:764-6. [DOI: 10.1002/hep.26789] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
29 Said VJ, Garcia-trujillo E. Beyond Lactulose: Treatment Options for Hepatic Encephalopathy. Gastroenterology Nursing 2019;42:277-85. [DOI: 10.1097/sga.0000000000000376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Orr JG, Currie CJ, Berni E, Goel A, Moriarty KJ, Sinha A, Gordon F, Dethier A, Dillon JF, Clark K, Richardson P, Middleton P, Patel V, Shawcross D, Preedy H, Aspinall RJ, Hudson M. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α. Liver Int 2016;36:1295-303. [PMID: 26950766 DOI: 10.1111/liv.13111] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
31 Ishikawa T, Aibe Y, Matsuda T, Iwamoto T, Takami T, Sakaida I. Plasma Glucose Level Is Predictive of Serum Ammonia Level After Retrograde Occlusion of Portosystemic Shunts. AJR Am J Roentgenol 2017;209:W169-76. [PMID: 28657848 DOI: 10.2214/AJR.16.17307] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
32 Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev 2019;6:CD012334. [PMID: 31204790 DOI: 10.1002/14651858.CD012334.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
33 Alukal JJ, Zhang T, Thuluvath PJ. Mortality and health care burden of Budd Chiari syndrome in the United States: A nationwide analysis (1998-2017). World J Hepatol 2021; 13(6): 686-698 [PMID: 34239703 DOI: 10.4254/wjh.v13.i6.686] [Reference Citation Analysis]
34 Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66:1727-1738. [PMID: 28586116 DOI: 10.1002/hep.29306] [Cited by in Crossref: 254] [Cited by in F6Publishing: 212] [Article Influence: 50.8] [Reference Citation Analysis]
35 Weiss N, Rosselli M, Mouri S, Galanaud D, Puybasset L, Agarwal B, Thabut D, Jalan R. Modification in CSF specific gravity in acutely decompensated cirrhosis and acute on chronic liver failure independent of encephalopathy, evidences for an early blood-CSF barrier dysfunction in cirrhosis. Metab Brain Dis 2017;32:369-76. [PMID: 27730496 DOI: 10.1007/s11011-016-9916-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
36 Shaw J, Bajaj JS. Covert Hepatic Encephalopathy: Can My Patient Drive? J Clin Gastroenterol 2017;51:118-26. [PMID: 28027071 DOI: 10.1097/MCG.0000000000000764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
37 Basu PP, Shah NJ. Clinical and Neurologic Manifestation of Minimal Hepatic Encephalopathy and Overt Hepatic Encephalopathy. Clin Liver Dis. 2015;19:461-472. [PMID: 26195201 DOI: 10.1016/j.cld.2015.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
38 Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;5:CD001939. [PMID: 28518283 DOI: 10.1002/14651858.cd001939.pub4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
39 Olesen SS, Jackson CD, Gram M, Zacharias HD, Dirks M, Weissenborn K, Drewes AM, Morgan MY. Cortical networks are disturbed in people with cirrhosis even in the absence of neuropsychometric impairment. Clin Neurophysiol 2019;130:419-27. [PMID: 30552046 DOI: 10.1016/j.clinph.2018.11.011] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Bloom A, Mudiyansalage VW, Rhodes A, Hogg M, Jayasekera C, Gorelik A, Sood S, Nicoll A. Can adequate analgesia be achieved in patients with cirrhosis without precipitating hepatic encephalopathy? A prospective study. Clin Exp Hepatol 2020;6:243-52. [PMID: 33145431 DOI: 10.5114/ceh.2020.99521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Orman ES, Mayorga ME, Wheeler SB, Townsley RM, Toro-Diaz HH, Hayashi PH, Barritt AS 4th. Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transpl. 2015;21:1040-1050. [PMID: 25939487 DOI: 10.1002/lt.24160] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
42 Tsai CF, Liu CJ, Chen TJ, Chu CJ, Lin HC, Lee FY, Su TP, Lu CL. Increased incidence of orthopedic fractures in cirrhotic patients: a nationwide population-based study. J Hepatol 2013;58:706-14. [PMID: 23238105 DOI: 10.1016/j.jhep.2012.12.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
43 Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M. Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepat Med. 2015;7:37-42. [PMID: 26203290 DOI: 10.2147/hmer.s87594] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
44 Duah A, Agyei-Nkansah A, Osei-Poku F, Duah F, Ampofo-Boobi D, Peprah B. The Prevalence, Predictors, and In-Hospital Mortality of Hepatic Encephalopathy in Patients with Liver Cirrhosis Admitted at St. Dominic Hospital in Akwatia, Ghana. Can J Gastroenterol Hepatol 2020;2020:8816522. [PMID: 33425806 DOI: 10.1155/2020/8816522] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Bajaj JS. Diagnosing minimal hepatic encephalopathy: from the ivory tower to the real world. Gastroenterology 2015;149:1330-3. [PMID: 26416330 DOI: 10.1053/j.gastro.2015.09.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
46 Cui Y, Guan S, Ding J, He Y, Li Q, Wang S, Sun H. Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy. Metab Brain Dis 2019;34:213-21. [DOI: 10.1007/s11011-018-0333-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Parekh PJ, Balart LA. Ammonia and Its Role in the Pathogenesis of Hepatic Encephalopathy. Clin Liver Dis. 2015;19:529-537. [PMID: 26195206 DOI: 10.1016/j.cld.2015.05.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
48 Ning Z, Shuangnan Z, Xiaohe X, Zhen W, Yunfeng B, Tingting H, Chao Z, Yao W, Zhou K, Zhongxia W, Bing L, Prokop LJ, Hernandez MC, Jun L, Man G. Rhubarb-based Chinese herbal formulae for hepatic encephalopathy: a systematic review and Meta-analysis. Journal of Traditional Chinese Medicine 2017;37:721-34. [DOI: 10.1016/s0254-6272(18)30035-9] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
49 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410. [PMID: 29762873 DOI: 10.1002/14651858.cd012410.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
50 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;CD003044. [PMID: 27153247 DOI: 10.1002/14651858.cd003044.pub4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
51 Neff G, Zachry W III. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin. Pharmacoeconomics 2018;36:809-22. [PMID: 29651649 DOI: 10.1007/s40273-018-0641-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
52 Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I, Martí-Amarista CE. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2019;1:CD011451. [PMID: 30610762 DOI: 10.1002/14651858.CD011451.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
53 Ishikawa T, Sasaki R, Nishimura T, Matsuda T, Maeda M, Iwamoto T, Saeki I, Hidaka I, Takami T, Sakaida I. Comparison of patients with hepatic encephalopathy and those with gastric varices before and after balloon-occluded retrograde transvenous obliteration. Hepatol Res 2018;48:1020-30. [PMID: 29882396 DOI: 10.1111/hepr.13199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
54 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;8:CD002798. [PMID: 28796283 DOI: 10.1002/14651858.CD002798.pub4] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Montagnese S, Russo FP, Amodio P, Burra P, Gasbarrini A, Loguercio C, Marchesini G, Merli M, Ponziani FR, Riggio O, Scarpignato C. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019;51:190-205. [PMID: 30606696 DOI: 10.1016/j.dld.2018.11.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
56 Mukund A, Chalamarla LK, Singla N, Shasthry SM, Sarin SK. Intractable hepatic encephalopathy in cirrhotic patients: mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration. Eur Radiol 2020;30:3462-72. [PMID: 32048037 DOI: 10.1007/s00330-019-06644-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Fallahzadeh MA, Rahimi RS. Hepatic Encephalopathy and Nutrition Influences: A Narrative Review. Nutr Clin Pract 2020;35:36-48. [PMID: 31872484 DOI: 10.1002/ncp.10458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Lewis DS, Lee T, Konanur M, Ziegler C, Hall MD, Pabon-ramos WM, Suhocki PV, Smith TP, Kim CY, Choi SS, Ronald J. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology 2019;30:163-9. [DOI: 10.1016/j.jvir.2018.10.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
59 Alsahhar JS, Rahimi RS. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy. Current Opinion in Gastroenterology 2019;35:145-54. [DOI: 10.1097/mog.0000000000000527] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Bai Z, Guo X, Tacke F, Li Y, Li H, Qi X. Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization. Therap Adv Gastroenterol 2019;12:1756284819881302. [PMID: 31636711 DOI: 10.1177/1756284819881302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
61 Kerbert AJC, Reverter E, Verbruggen L, Tieleman M, Navasa M, Mertens BJA, Rodríguez-Tajes S, de Vree M, Metselaar HJ, Chiang FWT, Verspaget HW, van Hoek B, Bosch J, Coenraad MJ. Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates. Clin Transplant 2018;32:e13412. [PMID: 30230613 DOI: 10.1111/ctr.13412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
62 Romero-gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Journal of Hepatology 2015;62:437-47. [DOI: 10.1016/j.jhep.2014.09.005] [Cited by in Crossref: 125] [Cited by in F6Publishing: 100] [Article Influence: 17.9] [Reference Citation Analysis]
63 Haj M, Hart M, Rockey DC. Development of a novel clinical staging model for cirrhosis using the Nationwide Inpatient Sample. J Investig Med 2018;66:992-7. [PMID: 29760160 DOI: 10.1136/jim-2018-000709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
64 Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis 2018;50:741-9. [PMID: 29807873 DOI: 10.1016/j.dld.2018.04.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
65 Pant C, Olyaee M, Gilroy R, Pandya PK, Olson JC, Oropeza-Vail M, Rai T, Deshpande A. Emergency department visits related to cirrhosis: a retrospective study of the nationwide emergency department sample 2006 to 2011. Medicine (Baltimore). 2015;94:e308. [PMID: 25569646 DOI: 10.1097/md.0000000000000308] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
66 Reuter B, Walter K, Bissonnette J, Leise MD, Lai J, Tandon P, Kamath PS, Biggins SW, Rose CF, Wade JB, Bajaj JS. Assessment of the spectrum of hepatic encephalopathy: A multicenter study. Liver Transpl 2018;24:587-94. [PMID: 29457869 DOI: 10.1002/lt.25032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
67 Zacharias HD, Zacharias AP, Oliveira Ferreira A, Morgan MY, Gluud LL; Cochrane Hepato-Biliary Group. Ammonia scavenging agents for people with cirrhosis and hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012334] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Gil-Gómez A, Ampuero J, Rojas Á, Gallego-Durán R, Muñoz-Hernández R, Rico MC, Millán R, García-Lozano R, Francés R, Soriano G, Romero-Gómez M. Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. Am J Gastroenterol 2021;116:1238-47. [PMID: 33852451 DOI: 10.14309/ajg.0000000000001164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther. 2015;41:39-45. [PMID: 25339518 DOI: 10.1111/apt.12993] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
70 DeMorrow S. Concise Commentary: Staying True to Type-The Increasing Inpatient Burden of Hepatic Encephalopathy. Dig Dis Sci 2019;64:1458-9. [PMID: 31037592 DOI: 10.1007/s10620-019-05630-6] [Reference Citation Analysis]
71 Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, Villalba J, Garcia-Pagan JC, Barrufet M, Jalan R, Brookes J, Thalassinos E, Burroughs AK, Cordoba J, Nevens F; EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57:2448-2457. [PMID: 23401201 DOI: 10.1002/hep.26314] [Cited by in Crossref: 143] [Cited by in F6Publishing: 105] [Article Influence: 15.9] [Reference Citation Analysis]
72 Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-450. [PMID: 30444745 DOI: 10.1097/meg.0000000000001311] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 7.3] [Reference Citation Analysis]
73 Lima LCD, Miranda AS, Ferreira RN, Rachid MA, Simões e Silva AC. Hepatic encephalopathy: Lessons from preclinical studies. World J Hepatol 2019; 11(2): 173-185 [PMID: 30820267 DOI: 10.4254/wjh.v11.i2.173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
74 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;7:CD002798. [PMID: 28745801 DOI: 10.1002/14651858.CD002798.pub3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
75 American Association for the Study of Liver Diseases. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642-659. [PMID: 25015420 DOI: 10.1016/j.jhep.2014.05.042] [Cited by in Crossref: 212] [Cited by in F6Publishing: 164] [Article Influence: 26.5] [Reference Citation Analysis]
76 Yi Z, Mayorga ME, Orman ES, Wheeler SB, Hayashi PH, Barritt AS Th. Trends in Characteristics of Patients Listed for Liver Transplantation Will Lead to Higher Rates of Waitlist Removal Due to Clinical Deterioration. Transplantation. 2017;101:2368-2374. [PMID: 28858174 DOI: 10.1097/tp.0000000000001851] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
77 Shaw J, Tate V, Hanson J, Bajaj JS. What diet should I recommend my patient with Hepatic Encephalopathy? Curr Hepatol Rep 2020;19:13-22. [PMID: 33457180 DOI: 10.1007/s11901-020-00510-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
78 Amodio P. Hepatic encephalopathy: Diagnosis and management. Liver Int. 2018;38:966-975. [PMID: 29624860 DOI: 10.1111/liv.13752] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
79 Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Aliment Pharmacol Ther 2019;49:1518-27. [PMID: 31032966 DOI: 10.1111/apt.15265] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
80 Hirode G, Vittinghoff E, Wong RJ. Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. Dig Dis Sci 2019;64:1448-57. [PMID: 30863953 DOI: 10.1007/s10620-019-05576-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
81 Zhao LN, Yu T, Lan SY, Hou JT, Zhang ZZ, Wang SS, Liu FB. Probiotics can improve the clinical outcomes of hepatic encephalopathy: An update meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:674-682. [PMID: 25956487 DOI: 10.1016/j.clinre.2015.03.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
82 Kerbert AJC, Jalan R. Recent advances in understanding and managing hepatic encephalopathy in chronic liver disease. F1000Res 2020;9:F1000 Faculty Rev-312. [PMID: 32399191 DOI: 10.12688/f1000research.22183.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
83 Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2015;2:CD001939. [PMID: 25715177 DOI: 10.1002/14651858.cd001939.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
84 De Rui M, Montagnese S, Amodio P. Recent developments in the diagnosis and treatment of covert/minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2016;10:443-50. [PMID: 26758861 DOI: 10.1586/17474124.2016.1141675] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
85 Nikolov P, Baumgarten TJ, Hassan SS, Meissner SN, Füllenbach ND, Kircheis G, Häussinger D, Jördens MS, Butz M, Schnitzler A, Groiss SJ. Altered motor cortical plasticity in patients with hepatic encephalopathy: A paired associative stimulation study. Clin Neurophysiol 2021;132:2332-41. [PMID: 34454259 DOI: 10.1016/j.clinph.2021.07.019] [Reference Citation Analysis]
86 Elsaid MI, John T, Li Y, Pentakota SR, Rustgi VK. The Health Care Burden of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:263-75. [DOI: 10.1016/j.cld.2020.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. Hepatology 2016;64:908-22. [PMID: 27081787 DOI: 10.1002/hep.28598] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
88 Ye JF, Ju J. Rifaximin for prevention and treatment of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2015; 23(7): 1090-1096 [DOI: 10.11569/wcjd.v23.i7.1090] [Reference Citation Analysis]
89 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044. [PMID: 27089005 DOI: 10.1002/14651858.cd003044.pub3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
90 Jawaro T, Yang A, Dixit D, Bridgeman MB. Management of Hepatic Encephalopathy: A Primer. Ann Pharmacother. 2016;50:569-577. [PMID: 27126547 DOI: 10.1177/1060028016645826] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
91 Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 2013;28:307-12. [PMID: 23389621 DOI: 10.1007/s11011-013-9383-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
92 Axelrod DA, Dzebisashvili N, Lentine K, Segev DL, Dickson R, Tuttle-Newhall E, Freeman R, Schnitzler M. Assessing variation in the costs of care among patients awaiting liver transplantation. Am J Transplant. 2014;14:70-78. [PMID: 24165015 DOI: 10.1111/ajt.12494] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
93 Hirode G, Vittinghoff E, Wong RJ. Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States. J Clin Gastroenterol. 2019;53:765-771. [PMID: 31135632 DOI: 10.1097/mcg.0000000000001229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
94 Park HY, Tsauo J, Shin JH, Kim PH. Percutaneous Transparaumbilical Embolization of Spontaneous Portosystemic Shunts for the Treatment of Hepatic Encephalopathy. J Vasc Interv Radiol 2017;28:1563-8. [PMID: 29056191 DOI: 10.1016/j.jvir.2017.04.028] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Ventura-Cots M, Concepción M, Arranz JA, Simón-Talero M, Torrens M, Blanco-Grau A, Fuentes I, Suñé P, Alvarado-Tapias E, Gely C, Roman E, Mínguez B, Soriano G, Genescà J, Córdoba J. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therap Adv Gastroenterol 2016;9:823-35. [PMID: 27803737 DOI: 10.1177/1756283X16658252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
96 Ferreira MDF, Salavati Schmitz S, Schoenebeck JJ, Clements DN, Campbell SM, Gaylor DE, Mellanby RJ, Gow AG, Salavati M. Lactulose drives a reversible reduction and qualitative modulation of the faecal microbiota diversity in healthy dogs. Sci Rep 2019;9:13350. [PMID: 31527716 DOI: 10.1038/s41598-019-50090-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Patidar KR, Thacker LR, Wade JB, Sterling RK, Sanyal AJ, Siddiqui MS, Matherly SC, Stravitz RT, Puri P, Luketic VA, Fuchs M, White MB, Noble NA, Unser AB, Gilles H, Heuman DM, Bajaj JS. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014;109:1757-1763. [PMID: 25178701 DOI: 10.1038/ajg.2014.264] [Cited by in Crossref: 99] [Cited by in F6Publishing: 79] [Article Influence: 12.4] [Reference Citation Analysis]
98 Amodio P, Canesso F, Montagnese S. Dietary management of hepatic encephalopathy revisited. Curr Opin Clin Nutr Metab Care. 2014;17:448-452. [PMID: 25025262 DOI: 10.1097/mco.0000000000000084] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
99 Haj M, Rockey DC. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020;115:723-728. [PMID: 31658104 DOI: 10.14309/ajg.0000000000000343] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
100 Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:157-74. [DOI: 10.1016/j.cld.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
101 Maggi DC, Borgonovo A, Bansho ET, Soares-silva PE, Silva TE, Colombo BS, Wildner LM, Bazzo ML, Dantas-correa EB, Narciso-schiavon JL, Schiavon LL. Serial assessment of hepatic encephalopathy in patients hospitalised for acute decompensation of cirrhosis. Annals of Hepatology 2019;18:331-7. [DOI: 10.1016/j.aohep.2018.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
102 Sussman NL. Treatment of Overt Hepatic Encephalopathy. Clin Liver Dis 2015;19:551-63. [PMID: 26195208 DOI: 10.1016/j.cld.2015.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
103 Shankar N, Ramani A, Griffin C, Agbim U, Kim D, Ahmed A, Asrani SK. Extrahepatic causes of death in cirrhosis compared to other chronic conditions in the United States, 1999-2017. Ann Hepatol 2021;26:100565. [PMID: 34728419 DOI: 10.1016/j.aohep.2021.100565] [Reference Citation Analysis]
104 Heslin KC, Elixhauser A, Steiner CA. Identifying in-patient costs attributable to the clinical sequelae and comorbidities of alcoholic liver disease in a national hospital database. Addiction 2017;112:782-91. [PMID: 27886658 DOI: 10.1111/add.13702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
105 Stepanova M, Venkatesan C, Altaweel L, Mishra A, Younossi ZM. Recent Trends in Inpatient Mortality and Resource Utilization for Patients with Stroke in the United States: 2005-2009. Journal of Stroke and Cerebrovascular Diseases 2013;22:491-9. [DOI: 10.1016/j.jstrokecerebrovasdis.2013.03.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
106 Saab S. Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy. Int J Gen Med. 2015;8:165-173. [PMID: 25999756 DOI: 10.2147/ijgm.s81878] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
107 Gluud LL, Jeyaraj R, Morgan MY. Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy. J Clin Exp Hepatol 2019;9:354-61. [PMID: 31360028 DOI: 10.1016/j.jceh.2019.02.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Al-taee AM, Khneizer GW, Mohammed KA, Neuschwander-tetri BA. Alarming trends in hepatic encephalopathy in the USA. European Journal of Gastroenterology & Hepatology 2019;31:1165-6. [DOI: 10.1097/meg.0000000000001430] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Kruger AJ, Aberra F, Black SM, Hinton A, Hanje J, Conteh LF, Michaels AJ, Krishna SG, Mumtaz K. A validated risk model for prediction of early readmission in patients with hepatic encephalopathy. Annals of Hepatology 2019;18:310-7. [DOI: 10.1016/j.aohep.2018.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
110 Martel-Laferrière V, Homberger C, Bichoupan K, Dieterich DT. MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy. BMC Gastroenterol 2014;14:185. [PMID: 25326084 DOI: 10.1186/1471-230X-14-185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
111 Brahmania M, Wiskar K, Walley KR, Celi LA, Rush B. Lower household income is associated with an increased risk of hospital readmission in patients with decompensated cirrhosis. J Gastroenterol Hepatol 2021;36:1088-94. [PMID: 32562577 DOI: 10.1111/jgh.15153] [Reference Citation Analysis]
112 Liu A, Perumpail RB, Kumari R, Younossi ZM, Wong RJ, Ahmed A. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World J Hepatol 2015; 7(29): 2871-2879 [PMID: 26692331 DOI: 10.4254/wjh.v7.i29.2871] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
113 Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver. 2016;10:509-519. [PMID: 27377741 DOI: 10.5009/gnl15419] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
114 Hayward KL, Patel PJ, Valery PC, Horsfall LU, Li CY, Wright PL, Tallis CJ, Stuart KA, Irvine KM, Cottrell WN, Martin JH, Powell EE. Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. Hepatol Commun 2019;3:620-31. [PMID: 31061951 DOI: 10.1002/hep4.1334] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
115 Liotta EM, Romanova AL, Lizza BD, Rasmussen-Torvik LJ, Kim M, Francis B, Sangha RS, Carroll TJ, Ganger D, Ladner DP, Naidech AM, Paparello JJ, Prabhakaran S, Sorond FA, Maas MB. Osmotic Shifts, Cerebral Edema, and Neurologic Deterioration in Severe Hepatic Encephalopathy. Crit Care Med 2018;46:280-9. [PMID: 29341965 DOI: 10.1097/CCM.0000000000002831] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 5.3] [Reference Citation Analysis]
116 Liotta EM, Karvellas CJ, Kim M, Batra A, Naidech A, Prabhakaran S, Sorond FA, Kimberly WT, Maas MB. Serum osmolality, cerebrospinal fluid specific gravity and overt hepatic encephalopathy severity in patients with liver failure. Liver Int 2020;40:1977-86. [PMID: 32020734 DOI: 10.1111/liv.14400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Bannister CA, Orr JG, Reynolds AV, Hudson M, Conway P, Radwan A, Morgan CL, Currie CJ. Natural History of Patients Taking Rifaximin-α for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. Clin Ther 2016;38:1081-1089.e4. [PMID: 27136714 DOI: 10.1016/j.clinthera.2016.03.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
118 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43 Suppl 1:11-26. [PMID: 26618922 DOI: 10.1111/apt.13435] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
119 Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol 2015;13:2048-61. [PMID: 26164219 DOI: 10.1016/j.cgh.2015.06.039] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 12.4] [Reference Citation Analysis]
120 Liere V, Sandhu G, DeMorrow S. Recent advances in hepatic encephalopathy. F1000Res. 2017;6:1637. [PMID: 29026534 DOI: 10.12688/f1000research.11938.1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
121 Chaney A, Werner KT, Kipple T. Primary Care Management of Hepatic Encephalopathy: A Common Cirrhosis Complication. The Journal for Nurse Practitioners 2015;11:300-6. [DOI: 10.1016/j.nurpra.2014.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
122 Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós À, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Ginés P, Bernardi M. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol. 2014;60:275-281. [PMID: 24128414 DOI: 10.1016/j.jhep.2013.10.004] [Cited by in Crossref: 161] [Cited by in F6Publishing: 140] [Article Influence: 17.9] [Reference Citation Analysis]
123 Farkas ZC, Rashid T, Chen YS, Siddiqui TM, Yandrapalli S, Frager S, Aronow WS, Bodin R, Maddineni S. The correlation between sarcopaenia and post-transjugular intrahepatic portosystemic shunt hepatic encephalopathy: a single-institution review. Arch Med Sci Atheroscler Dis. 2019;4:e89-e93. [PMID: 31211275 DOI: 10.5114/amsad.2019.85380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
124 Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, Tallis CJ, Stuart KA, Wright PL, Smith DD, Irvine KM, Powell EE, Cottrell WN. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World J Gastroenterol 2017; 23(40): 7321-7331 [PMID: 29142479 DOI: 10.3748/wjg.v23.i40.7321] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
125 Kanwal F. Decreasing mortality in patients hospitalized with cirrhosis. Gastroenterology. 2015;148:897-900. [PMID: 25805421 DOI: 10.1053/j.gastro.2015.03.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
126 Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev 2015;90:55-68. [PMID: 25895618 DOI: 10.1016/j.addr.2015.04.009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
127 Yuan LT, Chuah SK, Yang SC, Liang CM, Wu CK, Tai WC, Hung TH, Nguang SH, Wang JW, Tseng KL, Ku MK, Hsu PI, Wu DC, Hsu CN. Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis. PLoS One. 2018;13:e0197127. [PMID: 29746564 DOI: 10.1371/journal.pone.0197127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
128 Rosenblatt R, Yeh J, Gaglio PJ. Long-Term Management: Modern Measures to Prevent Readmission in Patients with Hepatic Encephalopathy. Clin Liver Dis 2020;24:277-90. [PMID: 32245533 DOI: 10.1016/j.cld.2020.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
129 Pereira K, Carrion AF, Martin P, Vaheesan K, Salsamendi J, Doshi M, Yrizarry JM. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy. Liver Int. 2015;35:2487-2494. [PMID: 26332169 DOI: 10.1111/liv.12956] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
130 Orman ES, Perkins A, Ghabril M, Khan BA, Chalasani N, Boustani MA. The confusion assessment method for the intensive care unit in patients with cirrhosis. Metab Brain Dis 2015;30:1063-71. [PMID: 25947193 DOI: 10.1007/s11011-015-9679-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
131 Hoilat GJ, Ayas MF, Hoilat JN, Abu-Zaid A, Durer C, Durer S, Adhami T, John S. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis. BMJ Open Gastroenterol 2021;8:e000648. [PMID: 34006606 DOI: 10.1136/bmjgast-2021-000648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Hassanein T. Current state of knowledge of hepatic encephalopathy (part IV): Management of Hepatic Encephalopathy by liver support systems. Metab Brain Dis 2017;32:303-6. [PMID: 28013444 DOI: 10.1007/s11011-016-9911-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Cittolin-Santos GF, de Assis AM, Guazzelli PA, Paniz LG, da Silva JS, Calcagnotto ME, Hansel G, Zenki KC, Kalinine E, Duarte MM, Souza DO. Guanosine Exerts Neuroprotective Effect in an Experimental Model of Acute Ammonia Intoxication. Mol Neurobiol 2017;54:3137-48. [PMID: 27052954 DOI: 10.1007/s12035-016-9892-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
134 Coronado WM, Ju C, Bullen J, Kapoor B. Predictors of Occurrence and Risk of Hepatic Encephalopathy After TIPS Creation: A 15-Year Experience. Cardiovasc Intervent Radiol. 2020;43:1156-1164. [PMID: 32435836 DOI: 10.1007/s00270-020-02512-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
135 Chen HJ, Shi HB, Jiang LF, Li L, Chen R. Disrupted topological organization of brain structural network associated with prior overt hepatic encephalopathy in cirrhotic patients. Eur Radiol 2018;28:85-95. [PMID: 28667481 DOI: 10.1007/s00330-017-4887-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
136 Bloom PP, Tapper EB. The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy. J Clin Med 2020;9:E3620. [PMID: 33182743 DOI: 10.3390/jcm9113620] [Reference Citation Analysis]
137 Teperman LW. Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes. Int J Hepatol 2013;2013:952828. [PMID: 24324895 DOI: 10.1155/2013/952828] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
138 Bodek D, Patel P, Ahlawat S, Orosz E, Nasereddin T, Pyrsopoulos N. Superior Performance of Teaching and Transplant Hospitals in the Management of Hepatic Encephalopathy from 2007 to 2014. J Clin Transl Hepatol 2018;6:362-71. [PMID: 30637212 DOI: 10.14218/JCTH.2017.00078] [Reference Citation Analysis]
139 Saberifiroozi M. Improving Quality of Care in Patients with Liver Cirrhosis. Middle East J Dig Dis 2017;9:189-200. [PMID: 29255576 DOI: 10.15171/mejdd.2017.73] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
140 Bajaj JS, Riggio O, Allampati S, Prakash R, Gioia S, Onori E, Piazza N, Noble NA, White MB, Mullen KD. Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: An international multicenter study. Clin Gastroenterol Hepatol. 2013;11:1511-1516. [PMID: 23707462 DOI: 10.1016/j.cgh.2013.05.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
141 Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc 2014;89:241-53. [PMID: 24411831 DOI: 10.1016/j.mayocp.2013.11.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
142 Saboo K, Shamsaddini A, Iyer MV, Hu C, Fagan A, Gavis EA, White MB, Fuchs M, Heuman DM, Sikaroodi M, Iyer RK, Gillevet PM, Bajaj JS. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy. J Hepatol 2021;74:80-8. [PMID: 32679299 DOI: 10.1016/j.jhep.2020.06.046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Tsai CY, Su CH, Chan JY, Chan SH. Nitrosative Stress-Induced Disruption of Baroreflex Neural Circuits in a Rat Model of Hepatic Encephalopathy: A DTI Study. Sci Rep 2017;7:40111. [PMID: 28079146 DOI: 10.1038/srep40111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
144 Shah NL, Banaei YP, Hojnowski KL, Cornella SL. Management options in decompensated cirrhosis. Hepat Med 2015;7:43-50. [PMID: 26203291 DOI: 10.2147/HMER.S62463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
145 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
146 Ventura-Cots M, Carmona I, Moreno C, Ampuero J, Simón-Talero M, Sanpedro F, Les I, Romero-Gómez M, Genescà J. Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therap Adv Gastroenterol 2018;11:1756283X17743419. [PMID: 29383024 DOI: 10.1177/1756283X17743419] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
147 Volk ML, Burne R, Guérin A, Shi S, Joseph GJ, Heimanson Z, Ahmad M. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States. J Med Econ 2021;24:202-11. [PMID: 33464935 DOI: 10.1080/13696998.2021.1877148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Chen Z, Babcock A, Sanogo V, Nelson DR, Xiao H, Diaby V. Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014. Expert Rev Pharmacoecon Outcomes Res 2021;:1-7. [PMID: 33985399 DOI: 10.1080/14737167.2021.1927717] [Reference Citation Analysis]
149 Vadhariya A, Chen H, Serna O, Zamil H, Abughosh SM. A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine (Baltimore) 2020;99:e19603. [PMID: 32311928 DOI: 10.1097/MD.0000000000019603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
150 Li M, Zhang Z, Chen Q, Zhou X, Shui D, Huang J. Comparative Effectiveness and Safety of Polyethylene Glycol Electrolyte Solution Versus Lactulose for Treatment of Hepatic Encephalopathy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2022;56:41-8. [PMID: 34739404 DOI: 10.1097/MCG.0000000000001621] [Reference Citation Analysis]